QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

04.04.24 19:22 Uhr

Werte in diesem Artikel
Aktien

40,23 EUR 0,02 EUR 0,05%

Indizes

PKT PKT

18.693,4 PKT 2,1 PKT 0,01%

7.195,0 PKT -0,7 PKT -0,01%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

189,8 PKT 0,7 PKT 0,38%

521,8 PKT -0,2 PKT -0,04%

9.961,4 PKT 0,9 PKT 0,01%

18.702,0 PKT 2,0 PKT 0,01%

18.679,1 PKT 65,3 PKT 0,35%

3.428,9 PKT -7,0 PKT -0,20%

7.362,9 PKT 0,2 PKT 0,00%

3.437,4 PKT -12,6 PKT -0,36%

2.521,2 PKT -9,7 PKT -0,38%

3.965,1 PKT -10,8 PKT -0,27%

QIAGEN N.V. QGEN recently announced a sequence of new products to augment cancer research further and to enable urine collection and stabilization as a new approach for liquid biopsy. The three new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.The new products are likely to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, from Apr 5-10.Product DetailsThe first product introduced is QIAcuity dPCR PanCancer Kits. The kits will enable researchers to use QIAGEN's QIAcuity dPCR technique to detect several EGFR and BRAF signature mutations simultaneously and with high sensitivity. The technology has the potential to be adapted to identify other genes associated with cancer risks.To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors. With great precision and sensitivity, this library prep kit will expedite research in several areas, including the potential biomarker applications of the T-cell receptor repertoire in cancer and the enhancement of tumor-infiltrating T-cell repertoire knowledge.Later this year, PreAnalytiX, a joint venture between QIAGEN and BD, will introduce the PAXgene Urine Liquid Biopsy Set. It will bridge existing preanalytical workflow gaps for cell-free DNA in urine (ucfDNA) and offer a simple, non-invasive collection method for liquid biopsy.Image Source: Zacks Investment ResearchAside from showcasing its digital PCR technology growth from research to the clinical arena, QIAGEN will also highlight the impending debut of the QIAcuity system for IVD testing during the AACR meeting. Along with IVD functionality, the QIAcuityDx system offers a customized assay development environment.Benefits of New LaunchesPer QIAGEN management, the company is thrilled to share its most recent breakthrough in digital PCR, NGS, non-invasive sample collection and DNA stabilization with the research community. This will allow the community to acquire significant insights into cancer.The new QIAcuity PanCancer kits will improve understanding of EGFR- and BRAF-driven tumors. At the same time, the QIAcuity IVD system, set to emerge this summer, will turn cancer research into clinical applications and precision diagnostics.The company also stated that its innovative solutions for urine liquid biopsy and targeted RNA-sequencing provide researchers with new efficient tools that could help them discover minimal residual disease, track therapy response, and uncover novel therapeutic targets.Industry ProspectsPer Grand View Research, the global cancer diagnostics market size was estimated at $107.45 billion in 2023 and is expected to witness a CAGR of 6.16% from 2024 to 2030. The growth of this industry is attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures, and rising initiatives undertaken by private and public organizations.Other Notable HighlightsIn January 2024, QIAGEN announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, ‘One Health Microbiome Center,’ to support faculty and students.Earlier in November 2023, QIAGEN expanded its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples. The TissueLyser III complements the company’s portfolio of high-throughput instruments, which include QIAcube HT, QIAxcel Connect and QIAsymphony.Price PerformanceIn the past six months, QGEN’s shares have gained 0.5% compared with the industry’s rise of 10.9%.Zacks Rank and Key PicksQIAGEN currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks from the broader medical space are Stryker Corporation SYK, Cencora, Inc. COR and Cardinal Health CAH.Stryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.Cencora, carrying a Zacks Rank #2, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.Cardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.4 Oil Stocks with Massive UpsidesGlobal demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold." Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf QIAGEN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu QIAGEN N.V.

Analysen zu QIAGEN N.V.

DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
16.04.2024QIAGEN BuyDeutsche Bank AG
16.02.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN HoldJefferies & Company Inc.
01.03.2024QIAGEN NeutralUBS AG
DatumRatingAnalyst
17.02.2021QIAGEN VerkaufenIndependent Research GmbH
14.12.2020QIAGEN VerkaufenDZ BANK
10.12.2020QIAGEN VerkaufenIndependent Research GmbH
24.11.2020QIAGEN VerkaufenIndependent Research GmbH
11.11.2020QIAGEN VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"